Barely Significant
← all excerpts

Preclinical evaluation of a CCL19 immune-potentiated DNA cancer vaccine.

Cancer Immunol Immunother · 2025 · PMC12290162 · PMID 40705109

1
hedged sentence
closest p
boldest claim

The sentences

Although the difference between the combination group (mCCL19-CH3-Neo13+ a-PD-1 mAb) and the mCCL19-CH3-Neo13+ control antibody group did not reach statistical significance, a trend toward an additive effect was evident.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.